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Secretor-positive donorsHuman noroviruses are difﬁcult to study due to the lack of an efﬁcient in vitro cell culture system or small
animal model. Murine norovirus replicates in murine macrophages (MΦ) and dendritic cells (DCs), raising
the possibility that human NoVs might replicate in such human cell types. To test this hypothesis, we
evaluated DCs and MΦ derived from monocyte subsets and CD11c+ DCs isolated from peripheral blood
mononuclear cells of individuals susceptible to Norwalk virus (NV) infection. These cells were exposed to NV
and replication was evaluated by immunoﬂuorescence and by quantitative RT-PCR. A few PBMC-derived DCs
expressed NV proteins. However, NV RNA did not increase in any of the cells tested. These results
demonstrate that NV does not replicate in human CD11c+ DCs, monocyte-derived DCs and MΦ, but abortive
infection may occur in a few DCs. These results suggest that NV tropism is distinct from that of murine
noroviruses.robiology Department, Baylor
n, TX 77030, USA. Fax: +1 713
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Norwalk virus (NV) is the prototype strain in the Norovirus (NoV)
genus within the Caliciviridae family. TheNorovirus genus is divided in
5 genogroups, with genogroups GI, GII, and GIV containing human
strains, GIII containing bovine strains, and GV containing murine
norovirus (MNV) strains. NoVs are nonenveloped viruses with a
positive-sense, polyadenylated, single-stranded RNA genome. The
genome of ~7.7 kb encodes three open reading frames [(ORF)s 1, 2,
and 3]. ORF1 encodes a nonstructural polyprotein, and ORF2 and ORF3
code for the two capsid proteins, VP1 and VP2, respectively (Glass et
al., 2000; Jiang et al., 1992; Jiang et al., 1993). Human NoVs are the
most common cause of outbreaks and sporadic non-bacterial
gastroenteritis in the United States as well as the cause of signiﬁcant
disease in developing countries (Fankhauser et al., 1998; Mead et al.,
1999; Patel et al., 2008). Symptoms include severe vomiting, watery
diarrhea, nausea, abdominal cramps, fever and general malaise (Glass
et al., 2009). Since its discovery in 1972, study of these highly
contagious viruses has been difﬁcult due to the lack of an in vitro cellculture system or a small animal model for virus replication and
disease. Numerous attempts to develop amethod for the cultivation of
human NoVs have been unsuccessful (Duizer et al., 2004). Replication
systems in cells have been described but these remain inefﬁcient and
cannot be used to study fully permissive virus replication (Asanaka et
al., 2005; Katayama et al., 2006). A single report of cultivating human
NoVs in a 3-dimensional, organoid model of human small intestinal
epithelium has not been conﬁrmed (Herbst-Kralovetz et al., 2009;
Papafragkou et al., 2009; Straub et al., 2007). Gnotobiotic pigs and
calves can replicate genogroup II (GII) human NoVs and viremia is
detected (Cheetham et al., 2006; Souza et al., 2008), but currently no
culture system supports efﬁcient replication in vitro.
The MNV was originally isolated from immunodeﬁcient mice
(Karst et al., 2003) and can be propagated in cell culture (Wobus et al.,
2004). MNV infects macrophages (MΦ) and dendritic cells (DCs) in
vivo in STAT-1−/− mice, cultured bone-marrow-derived MΦ and
bone-marrow-derived DCs, as well as the several murine macrophage
cell lines and a human-murine hybrid macrophage cell line (Chango-
gotra et al., 2009; Wobus et al., 2004). These results, together with
data showing that NoVs can be detected in the serum of children with
gastroenteritis (Takanashi et al., 2009), raise the possibility that
human NoVs may replicate in cells of the hematopoietic lineage in
humans. Studies with volunteers challengedwith NV have shown that
genetically determined factors are responsible for resistance to NV
infection (Hutson et al., 2002; Hutson et al., 2005; Lindesmith et al.,
2003; Marionneau et al., 2002; Parrino et al., 1977). In particular,
secretor status (Se) of an individual, determined by the presence of
2 M.K. Lay et al. / Virology 406 (2010) 1–11functional α(1,2)fucosyltransferase (FUT2) gene products, regulates
susceptibility to NV infection (Hutson et al., 2005; Lindesmith et al.,
2003). The FUT2 enzyme produces H antigens on the surface of
epithelial cells and inmucosal secretions (Kelly et al., 1995), and these
glycans are thought to function as an initial receptor for NV (Guix et al.,
2007). Thus, cells from histoblood group type O and Se positive (Se+)
individuals bind to NV and are thought to be more susceptible to
infection than those from Se negative (Se−) individuals (Marionneau
et al., 2002). In this study, we tested the hypothesis that NV has a
tropism for human monocyte-derived DCs and MΦ and circulating
CD11c+ DCs obtained from PBMCs of blood group O, Se+ donors.Fig. 2. Effect of γ-irradiation on NV genomic RNA qRT-PCR detection. NV puriﬁed from
stools was exposed to different γ-irradiation doses (black dots) expressed in kilo Gray
units (kGy); or left unexposed at room temperature for equivalent periods of time
(white dots). Quantitation of NV RNA was performed by IMC/qRT-PCR, using primers
speciﬁc for the ORF1 region of the NV genome. The percentage of remaining ORF1 copy
numbers is shown on an exponential scale. Lineal regression curves were calculated as
r2=0.994 for γ-irradiated NV samples. Each dot represents 12 replicas.Results
Preparation of NV stocks for infectivity trials
NV inocula to perform infectivity experiments in DCs and MΦ
were prepared by purifying NV from stools containing high viral titers
from a NV-infected individual as previously described (Guix et al.,
2007). Brieﬂy, NV was puriﬁed by CsCl gradients and fractions
corresponding to CsCl densities of 1.37 to 1.39 g/ml were pooled and
used as a viral stock (Fig. 1). The presence of NV particles in this pool
was conﬁrmed by real-time quantitative (q) reverse transcriptase
(RT)-PCR and electron microscopy (data not shown). NV stocks
puriﬁed in this gradient for infectivity studies had a viral titer ranging
from 5×108 to 1.6×109 NV genome copies/μl, as estimated by
immunomagnetic capture (IMC)/qRT-PCR assay.
As a negative control, an aliquot of this NV stock was treated with
γ-irradiation. This treatment inactivates virus infectivity while
retaining residual, potentially toxic substances from the initial stool
sample that could co-purify with virus particles. First, the γ-
irradiation dose that signiﬁcantly decreased NV RNA detection by
IMC/qRT-PCR was determined (Fig. 2). Unexposed (mock-irradiated)
NV, kept at room temperature (RT) for the same length of time as the
sample exposed to the highest γ-irradiation dose, was used as a
control. Progressively higher doses of γ-irradiation led to a log-linear
decline in NV copy number (Fig. 2). Interpolation from this linear
regression curve (r2=0.994) determined that 4 and 4.5 kGy were
sufﬁcient to decrease detection of the NV genome copy concentration
by 99.4 and 99.6%, respectively, andwere chosen to inactivate puriﬁed
NV for use as a negative control for viral replication. Inactivation of NV
viral infectivity with these doses of γ-irradiation was conﬁrmed by
complete abrogation of NV protein expression in NV RNA transfected
Huh-7 cells, performed in similar manner as previously described
(Guix et al., 2007) (data not shown).Fig. 1. NV quantiﬁcation in fractions from NV puriﬁed from stools by isopycnic CsCl
gradient ultracentrifugation. Genomic NV RNA in each fraction of the CsCl density
gradient was quantiﬁed by IMC/qRT-PCR, using primers speciﬁc for the ORF1 region of
the NV genome (squares). The buoyant density of each fraction was also determined by
measuring the refractive index (diamonds). Each square represents replicas of 3.Identiﬁcation of the secretor status of type O group donors by FUT2
genotyping assay
All donors whose buffy coat cells were used in the study were
blood type O and their secretor status was determined by FUT2
genotyping assay, which identiﬁes the single nucleotide polymorph-
isms G428A (found in more than 95% of non-secretors of European
and African descent) and A385T (found in non-secretors of Asian
ancestry) that most commonly lead to dysfunction of the FUT2 gene
product, as previously described (Hutson et al., 2005). Among 15
donors tested, twelve were Se+, and three were Se− as determined by
the homozygosity of nucleotide A at position 428 (Table 1). Different
cell types were obtained from the donors for use in infectivity trials, as
summarized in Table 1. Cells from Se+ donors were used in most
trials, and cells from Se− donors were included in some studies as an
additional negative control.Table 1
Secretor status of donors and the different cell types used in this study, determined by
the FUT2 genotyping assays.
Donor # Cell type Secretor
status (Se)
FUT2 gene SNPs
G428Aa A385Ta
1 PBMC-DCs + GA AA
4 PBMC-DCs + GA AA
30 CD11c+ DCs + GG AA
56 CD14+/CD16+ DCs − AA AA
57 CD14+/CD16+ DCs − AA AA
58 CD14+/CD16+ DCs + GA AA
72 CD14+/CD16+ MΦ + GG AA
103 CD11c+ DCs + GA AA
369 PBMC-DCs + GA AA
453 PBMC-DCs + GG AA
698 PBMC-DCs + GA AA
748 CD14+/CD16+ MΦ + GG AA
778 PBMC-DCs + GA AA
829 PBMC-DCs + GA AA
907 CD11c+ DCs − AA AA
a Most common single nucleotide polymorphisms (SNP) of the FUT2 gene leading to
lack of function. Homozygous AA at 428 or TT at 385 deﬁnes Se− genotype.
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monocyte-derived DCs from type O/Se+ individuals
Characterization of PBMC monocyte-derived immature DCs
(PBMC-DCs) obtained by the adherence method was performed by
ﬂow cytometry analysis after GM-CSF and IL-4 treatment for 6 days, as
described in Materials and methods. These cells displayed a typical
proﬁle of expression of surface markers for immature DCs: high
expression of CD11c, CD1a, CD209, MHC-I, MHC-II, and low
expression of CD14. Most of these cells did not show upregulated
expression of mature DC markers, e.g., CD80, CD83, CD86 and CD40
(data not shown). We also determined the percentage of cells
expressing both CD11b+ and CD11c+ and CD11c+ cells expressing
CX3CR1+ or CD103+ in this PBMC-DC population (Supplementary
Fig. 1). The CX3CR1+ and CD103+ cell surface markers deﬁne two
distinct DC populations in the intestinal lamina propria (Bogunovic
et al., 2009; Jaensson et al., 2008; Varol et al., 2009). Most of the gated
cells (86.8%), initially isolated using the adherence method, were
positive for both CD11b+ and CD11c+ surface markers, typical
ﬁndings for DCs. In addition, most (86.9%) of the CD11c+ cells
expressed CX3CR1+ and only a small percentage (3.97%) of CD11c+
cells expressed CD103+ (Supplementary Fig. 1). To determine
whether PBMC-DCs support NV replication, cells from several donors
[1, 4, 369 and 698 (type O/Se+ individuals)], were inoculated with
puriﬁed NV stocks at multiplicities of infection ranging from 275 to
1941 NV genome copies/cell. Mock-inoculated (media only) and γ-
irradiated NV (4 kGy or 4.5 kGy) were used as negative controls.
Expression of viral protein and increases in viral RNA were analyzed
by immunoﬂuorescence (IF) and qRT-PCR, respectively. As deter-
mined by IF at 24 h post-inoculation (hpi), the capsid protein VP1 and
the nonstructural proteins VPg were co-expressed in 2–3 cells per
4×104 cells from donor 1 (Figs. 3A–C). Similar results were obtained
with cells from donors 4 and 369 (data not shown). After 72 hpi, no
increase in the number of cells expressing viral antigen was detected.
Moreover, VP1 and the nonstructural polymerase protein were co-
expressed in similar numbers of cells from donors 369 and 698 (data
not shown). No ﬂuorescence was observed in NV exposed cells
stained using a corresponding pre-immune serum as the primary
antibody, or in mock exposed cells (data not shown). Finally, we
infected these DCs with H1N1 (A/TX/36/91) and H3N2 (A/Brisbane/
10/2007) inﬂuenza virus strains and observed signiﬁcant cytopathic
effect and positive IF staining for the nucleoprotein in the majority ofFig. 3. Detection of NV proteins by immunoﬂuorescence in a few PBMCmonocyte-derived DC
were dual labeled with antibodies speciﬁc for VP1 (NV capsid protein) and for VPg (NV non
(A, B and C). Antibodies were visualized with species-speciﬁc IgG conjugated to Alexa Fluor 59
Phase contrast image of the stained cells (D). White scale bar represents 20 μm (upper panel)cells (data not shown). These results indicate that the PBMC-DCs used
in these experiments could support virus replication.
To identify what kind of DCs were expressing NV proteins, we also
dual labeled cells with antibodies speciﬁc for CX3CR1 and for CD103
surface cell markers. We found that VP1 expression in a few (0.5%)
CX3CR1+ cells (Figs. 4A–D), but not in CD103+ cells (Figs. 4E–H).
Despite this ﬁnding, the titer of NV genome copies in total pooled RNA
extracted from both the culture supernatant and cells of the
inoculated PBMC-DCs did not increase from time 0 to 24–72 hpi
(Fig. 5A). Similar results were obtained in three separate inoculation
experiments using cells from donor 4 (data not shown). Additionally,
no increase in NV RNA was observed up to 144 hpi. (Fig. 5B). These
results indicate that efﬁcient, productive replication did not occur in
human PBMC-DCs inoculated with NV even though a few isolated
CX3CR1+ DCs expressed viral antigens.
The type I IFN pathway does not affect NV replication in PBMC-DCs from
type O Se+ individuals
Since the NV inoculum was puriﬁed from stools from a NV-
infected individual, we evaluated the viral inoculum for the presence
of endotoxin (LPS). We determined that NV and γ-NV contained
200 ng/ml and 20 ng/ml of LPS, respectively. We next examined
whether the NV inoculummight induce upregulation of the type I IFN
pathway, a process that could lead to inhibition of NV replication in
PBMC-DCs. The NV inoculum (1941 genomic copies/cell), which
contained only 1.6 ng/ml of LPS, did not signiﬁcantly induce IFN-β
mRNA production in PBMC-DCs (donor 829) at 10 hpi as measured by
relative quantiﬁcation (RQ) qRT-PCR compared to mock exposed cells
(data not shown), while LPS (1 μg/ml) and poly-IC (50 μg/ml) did
signiﬁcantly increase IFN-β mRNA production 16- and 32-fold,
respectively (data not shown). To further assess whether upregula-
tion of the type I IFN pathway by the NV inoculum may have had an
effect on NV replication in PBMC-DCs, we inoculated PBMC-DCs
(donor 778) with NV treated with 10 μg/ml polymyxin B, an
antagonist of LPS (Inden et al., 2009). No increase in NV RNA was
observed in these cells at 72 hpi (Fig. 5B). In addition, NV-inoculated
PBMC-DCs (donor 453) treated with a cocktail of antibodies against
IFN-α, IFN-β and IFN-α/β receptor (anti-IFNs Abs), as previously
reported (Hanabuchi et al., 2006), did not result in an increase in
levels of NV RNA at 72 hpi (Fig. 5C). Similarly, no increase in the
number of VP1 positive cells was observed by IF in NV-inoculated DCss inoculated with NV. NV-inoculated PBMC-DCs from a type O/Se+ individual (donor 1)
structural protein). A few cells (2–3 out of 4×104 cells) express VP1 and VPg proteins
4 and 488, respectively. DAPI staining speciﬁc for nuclei was also performed (A, B and C).
; an enlargement of the boxed area (lower panel).
Fig. 4. NV protein expressing cells co-localize with some CX3CR1+ cells, but not with CD103+ cells by immunoﬂuorescence. NV-inoculated PBMC-DCs from a type O/Se+ individual
(donor 698) were stained with antibodies speciﬁc for CX3CR1 cell surfacemarker (A) and for capsid protein VP1 (B). Antibodies were visualized with species-speciﬁc IgG conjugated
to Alexa Fluor 488 and 594, respectively. Similar staining was performed with antibodies speciﬁc for CD103 surface marker (E) and for VP1 (F). Merge images from the respective co-
staining are shown in C and G. DAPI staining speciﬁc for nucleus was also performed (A, B, C, E, F and G). Phase contrast images of the stained cells (D and H). White scale bar
represents 20 μm.
Fig. 5. Detection of genomic NV RNA in PBMC monocyte-derived DCs inoculated with NV by qRT-PCR. Total RNA combined from the cells and the supernatant of PBMC-DCs from a
type O/Se+ individual (donor 1) exposed to mock (white triangles), or γ-irradiated NV (black triangles) or 275 NV genome copies/cell (white circles) or 1800 NV genome copies/
cell (black circles) of NV puriﬁed from stool, was analyzed by qRT-PCR, using primers speciﬁc to ORF1, at 0, 24 and 72 hpi (A). Total RNA from PBMC-DCs inoculated with NV
compared to NV-inoculated PBMC-DCs (donor 778) treated with 10 μg/ml polymixin B (B); or NV-inoculated PBMC-DCs (donor 453) treated with a cocktail of antibodies against
IFN-α, IFN-β and IFN-α/β receptor (C) were analyzed by qRT-PCR at different times. Total ORF1 copy numbers per well are represented on a log10 scale. Each well contained from 4
to 7×105 cells. The data plotted represent the means±standard deviation of triplicate wells. Dashed lines represent the detection limit of the assay. All points below the limit of
detection had the same value but were offset for visualization.
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(data not shown). Taken together, these results indicate that the
replication of NV in these cells was not inhibited by the induction of
the type I IFN pathway by the NV inoculum.
NV does not replicate in human CD14+ and CD16+ monocyte-derived
DCs, and CD11c+ blood DCs from type O/Se+ individuals
Since positive staining for NV proteins was observed in a few
CX3CR1 cells from PBMC-DCs, we determinedwhether NVmight have
a tropism for either one or both types of DCs derived by in vitro
differentiation from the two principal subsets (CD16high and CD14low,
and CD14high and CD16low) of human monocytes (Passlick et al.,
1989), that are reported to both express CX3CR1 (Seidler et al., 2010).
In addition, we also evaluated whether NV replicates in a directly
sorted, puriﬁed population of CD11c+ DCs, which are primary
committed-DCs circulating in the peripheral blood (Ito et al., 2005).
To test these hypotheses, ﬁrst human CD14+ and CD16+ monocyte
subsets were isolated from PBMCs of type O/Se+ or Se− individuals
and differentiated into immature DCs. Characterization of the two
isolated monocyte populations and monocye-derived DCs was
performed by ﬂow cytometry analysis at days 0 and 8 after GM-CSF
and IL-4 treatment (Supplementary Fig. 2). At day 0, the purity of
CD16+ and CD14+ monocytes was 77.9% and 78.4%, respectively
(Supplementary Figs. 2A and B, respectively). CD3 and CD56 expres-
sion was absent in both populations, indicating no contaminationFig. 6. NV does not replicate in CD16+, CD14+ monocyte-derived DCs or CD11c+ blood DC
mock, γ-NV and NV after 48 hpi by phase contrast microscopy (A). The titer of NV RNA in each
Se+ (donor 58) and type O/Se− (donor 56) individuals; and CD11c+ DCs (D) from a type
targeting the ORF1 region of the NV genomic RNAwere used. Total ORF1 copy numbers per w
plotted represent themeans±standard deviation of 6 (B and C) or 4 (D) replicate wells. Dash
had the same value but were offset for visualization.with T cells or NK cells in either of the two isolated monocyte
populations (data not shown). CD11c (highly expressed in cells of
myeloid origin) expression corresponded to 98% and 95% in CD16+
and CD14+ monocyte subsets, respectively (Supplementary Figs. 2A
and B, respectively). Analysis at day 8 showed that both populations
of CD16+ and CD14+ monocytes differentiated to immature DCs
(CD16+ DCs and CD14+ DCs, respectively), as indicated by the
upregulation of a major DCmarker CD1a, moderate and low expression
of the co-stimulatory molecules CD80 and CD40, and low expression of
CD16+ and CD14+monocyte markers, respectively. High expression of
MHC-I and MHC-II markers present in both monocyte subsets at day 0
and monocyte-derived DCs at day 8 is consistent with the antigen
presenting properties of these cells (Supplementary Figs. 2A and B).
CD11c+ DCs were isolated from PBMCs and characterized as previously
reported (Reche et al., 2001).
The CD16+ DC, CD14+ DC subsets and CD11c+ DCs were exposed
to NV, to γ-irradiated NV, or to media only (mock). Differences in cell
morphology were observed among the different DC subsets by light
microscopy, but no morphological changes were observed between
cells exposed to NV compared to the negative controls, indicating that
no cytopathic effect occurred (Fig. 6A). Positive IF staining for VP1 and
VPg NV proteins was observed only in a few (2 cells per 4×104 cells)
CD14+ DCs cells from a type O/Se+ (donor 1). No ﬂuorescence was
observed in γ-NV exposed or in NV exposed cells stained using a
corresponding pre-immune serum as the primary antibody (data not
shown). In addition, levels of viral RNA measured by qRT-PCR did nots. Analysis of cell morphology of CD16+ DCs, CD14+ DCs, and CD11c+ DCs exposed to
sample: mock, γ-NV and NV exposed CD16+ DCs (B) and CD14+ DCs (C), from type O/
O/Se+ (donor 103) individual, was measured by qRT-PCR at 0, 48 or 72 hpi. Primers
ell are represented on a log10 scale. Each well contained from 2 to 4×105 cells. The data
ed lines represent the detection limit of the assay. All points below the limit of detection
6 M.K. Lay et al. / Virology 406 (2010) 1–11increase from 0 to 72 hpi in any of the trials performed with the NV-
inoculated CD14+ DCs (Fig. 6B) and the NV-inoculated CD16+ DCs
(Fig. 6C) from type O/Se+ (donor 58) and Se− (donor 56) individuals.
Finally, no increase was observed either in levels of total viral RNA in
CD11c+ DCs from a type O/Se+ individual (donor 103) or from a Se−
individual (donor 907, data not shown) exposed to NV for 48 h
(Fig. 6D). These results demonstrate that NV does not replicate in
CD16+ DCs, CD14+ DCs and CD11c+ DCs from peripheral blood,
indicating that NV does not productively replicate in CD11c+ DCs
isolated directly from PBMCs and DCs derived from the two main
subsets of circulating monocytes from type O/Se+ individuals.
NV does not replicate in human CD14+ and CD16+ monocyte-derived
MΦ from type O/Se+ individuals
Wealso testedwhetherNVhas a tropism for either oneorboth of the
two MΦ subsets derived from human CD14+ and CD16+ monocytes.
After 7 days of treatment with M-CSF, CD14+ and CD16+ monocyte-
derived MΦ subsets ( CD14+ MΦ and CD16+ MΦ, respectively) were
exposed to NV, to γ-irradiated NV, or to media only (mock). No
morphological changes were observed in these different MΦ subsets
exposed toNV compared to the negative controls (Fig. 7A). As expected,
levels of viral RNA measured by qRT-PCR in γ-NV-inoculated CD14+
MΦ (Fig. 7B) and γ-NV-inoculated CD16+MΦ (Fig.7C) did not increase
over time. In addition, viral RNAdidnot increase in eitherNV-inoculated
CD14+MΦ (Fig. 7B)orNV-inoculatedCD16+MΦ (Fig. 7C) from typeO/
Se+ (donors 72 and 748) individuals after 72 hpi. These results indicateFig. 7. NV does not replicate in CD14+ or CD16+monocyte-derived MΦ. Analysis of cell mor
to mock, γ-NV and NV after 48 hpi (A). The titer of NV RNA in each sample: mock, γ-NV and N
and 748), was measured by qRT-PCR at 0 and 72 hpi. Primers targeting the ORF1 region of th
log10 scale. Each well contained 2×105 cells. The data plotted represent the means±standar
the assay. All points below the limit of detection had the same value but were offset for visthat NV does not replicate in these two subsets of monocyte-derived
MΦ from type O/Se+ individuals.
Discussion
The major hurdle to working with human NoVs is the inability to
efﬁciently cultivate these viruses in cultured cells. This hurdle prevents
complete studies of the virus replication cycle or studies to assess the
public health hazard of detecting viral nucleic acid in food and
environmental samples. A single report of replication in a 3-dimensional
organoid model of human small intestinal epithelium has not been
conﬁrmed (Herbst-Kralovetz et al., 2009; Papafragkou et al., 2009;
Straub et al., 2007). Our laboratory has reported previous unsuccessful
attempts to cultivate human NoVs in a variety of cell lines (Duizer et al.,
2004). The present paper reports the results of inoculation of cells of
hematopoietic origin, studies that were performed because a murine
norovirus that causes systemic infection of mice and is proposed as a
model to study human NoVs (Wobus et al., 2006) is cultivatable in
murineMΦ andDCs (Wobus et al., 2004). In addition, humanNoVs have
been detected in serum samples from children with gastroenteritis and
in gnotobiotic calves infected with human NoVs (Souza et al., 2008;
Takanashi et al., 2009). These are interesting reports that are
reminiscent of the recent recognition that rotaviruses cause a viremia
in children and animals (Blutt and Conner, 2007) and that PBMCs from
adults are susceptible to infection with puriﬁed rotavirus (Mesa et al.,
2007). Furthermore, using a biopsy of a NV-infected individual after
24 hpi, viral capsid expressionhas beendetected inmononuclear cells inphology observed by phase contrast microscopy in CD14+MΦ and CD16+ MΦ exposed
V exposed CD14+MΦ (B), and CD16+MΦ (C) from type O/Se+ individuals (donors 72
e NV genomic RNA were used. Total ORF1 copy numbers per well are represented on a
d deviation of 4 (B) or 3 (C) replicate wells. Dashed lines represent the detection limit of
ualization.
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Graham, M.K. Estes), suggesting that cells in the lamina propria,
including DCs and MΦ, might be infected with NV. The precursors of
these cells are likely to be monocytes or other precursors of intestinal
DCs circulating in the blood (Bogunovic et al., 2009; Geissmann et al.,
2003; Varol et al., 2007; Varol et al., 2009).
We did not detect productive replication of NV in CD11c+ DCs
isolated directly from PBMCs, or in different subsets of PBMC
monocyte-derived DCs or MΦ for up to 144 hpi. This time frame
was chosen for our studies because recent results, using RNA
extracted from NV puriﬁed from stool samples of infected volunteers,
show that within this period of time the viral RNA transfected into
cultured cells replicates to high titers that are detectable even though
the infection does not spread beyond the initially RNA-transfected
cells (Guix et al., 2007). In these previous transfection studies, we
estimated that ~20,000 genomic copies of RNA were produced per
transfected cell. It is possible that we were not able to detect a low
level of NV replication from the 2 or 3 antigen positive cells (estimated
total virus yieldb105 genomic copies) per 103–104 inoculated cells
due to the high levels of NV inoculum used. However, efﬁcient
replication as seen in the murine norovirus system was not observed
in our studies with NV. It remains to be seen if other NoV strainsmight
replicate in such cells.
Several approaches were used in our current studies to allow
evaluation of the speciﬁcity of any potential replication. First, we used
cells from donors characterized to be blood type O, Se+ who
are known to be genetically susceptible to NV infection (Hutson
et al., 2005; Lindesmith et al., 2003), and cells from genetically-
resistant Se− donors were used as negative controls. In addition,
aliquots of the live virus inoculumwere inactivated with γ-irradiation
to allow assessment of the effects of any residual stool components
that might be present in the fractions of virus puriﬁed from stool. The
results in all the cells tested indicate that NV does not replicate in
CD11c+ DCs, DCs and MΦ derived from the two main monocyte
subsets from PBMCs, and no differences were observed between Se+
and Se− individuals. One might question if the puriﬁed virus used for
these experiments is truly infectious. Until positive results are
obtained in cultured cells, this question cannot be fully answered.
However, the RNA extracted from similar preparations of virus is
infectious in Huh-7 cells (Guix et al., 2007), and puriﬁcation and
characterization of recombinant virus-like particles (VLPs), using the
same puriﬁcation methods, result in particles that are antigenically
and morphologically identical to authentic virus (Green et al., 1993;
Jiang et al., 1992). Moreover, VLPs also bind and enter cells that
express the needed histoblood group antigens (Guix et al., 2007;
Marionneau et al., 2002;White et al., 1996). The DCs from the Se+, but
not the Se− individuals, used in the current studies expressed
histoblood group antigens as shown by positive binding of NV VLPs
(data not shown). Murine norovirus puriﬁed in a similar manner also
retains its infectivity (Changotra et al., 2009).
While NV RNA does not efﬁciently replicate in these cells of
myeloid origin inoculated with virus, rare PBMC-derived DCs were
found to be positive for both the NV VP1 and VPg proteins by IF at 24
and 72 hpi (data not shown). These results suggest that, in a subset of
cells, abortive expression of the viral proteins or limited virus
replication may occur. We also tried to identify these cells using
two cell surface markers, which deﬁne two distinct (CX3CR1 and
CD103) DC populations in the intestinal lamina propria (Bogunovic
et al., 2009; Jaensson et al., 2008; Varol et al., 2009); VP1 expression
was detected in a few CX3CR1+ cells, but not in CD103+ cells. One
possibility is that these few permissive cells might represent DCs
derived from CD14+ or CD16+ monocytes, which both are known to
express CX3CR1 (Seidler et al., 2010), present in the peripheral blood
and are suggested to seed the lamina propria for renewal of DCs or
MΦ (Geissmann et al., 2003; Niess et al., 2005; Varol et al., 2007).
However, our results failed to detect efﬁcient replication in either typeof DCs and MΦs derived from these subsets of monocytes present in
the peripheral blood of individuals susceptible to NV infection.
Our negative culture results cannot provide an explanation for the
NV capsid-speciﬁc staining observed in cells of the intestinal lamina
propria in the above-mentioned biopsy. It remains possible that NV
might replicate in intestinal DC or MΦ that, under the local
microenvironment that inﬂuences the phenotype of these cells
(Niess, 2008; Smith et al., 2005), may have different properties from
those of PBMC-derived cells. Another possibility is that these cells may
come from precursors, which are different from the two main subsets
of monocytes present in the peripheral blood. A third possibility is
that replication was not occurring in these cells but, instead, these
cells took up viral capsid antigen by phagocytosis. Further studies will
be required to test human DCs or MΦ already differentiated in the
lamina propria of the intestine to see if they might support the
replication of NV or other human NoVs.
Our results suggest that the human NV possesses distinct
biological properties from the only norovirus, MNV, that replicates
efﬁciently in cultured primary, bone marrow-derived murine DCs and
MΦ as well as several murine macrophage cell lines and a human-
murine hybrid macrophage cell line in vitro (Changotra et al., 2009;
Wobus et al., 2004). In fact, to date there are no reports of MNVs
failing to replicate in any macrophage cell line of murine origin. Thus,
if the lack of efﬁcient replication of NV in human blood-derivedMΦ or
DCs and CD11c+ DCs was due to the source of these cells (i.e., not
derived from the bone marrow and differentiated in vitro), this would
contrast with the apparently more diverse tropism of MNVs for
murine macrophage cell lines. Another difference between human NV
and murine strains is that MNV-1 causes extraintestinal infection,
including encephalitis, in immunocompromised mice (Karst et al.,
2003) and extraintestinal infection in immunocompetent mice, but it
does not cause frank gastrointestinal disease or obvious detrimental
effects in immunocompetent mice (Henderson, 2008; Mumphrey
et al., 2007; Wobus et al., 2006). In addition, human NoVs bind to
histoblood group antigens likely as initial receptors (Marionneau
et al., 2002), and these antigens are host susceptibility factors for
human infection. In contrast, MNV is reported to bind to a ganglioside-
linked sialic acids on RAW 264.7 cells (Taube et al., 2009) and no
genetic host susceptibility factors have been identiﬁed in immuno-
competent mice, although immunocompromised interferon (IFN)- R
and STAT-1 knock-out mice are highly susceptible to infection and
disease (Karst et al., 2003; Mumphrey et al., 2007). Thus, the cell
tropisms for the MNVs and human NoVs in their respective hosts
appear to be quite distinct.
Resistance to NV replication of the DCs andMΦ tested in this study
might have been due to strong IFN responses produced in these cells.
IFN-α and IFN-γ have been recently reported to play a pivotal role in
controlling replication of a NV replicon in human hepatoma cells
(Huh-7 cells) or hamster kidney cells (BHK21 cells) (Chang et al.,
2006; Chang and George, 2007), suggesting that IFN production is an
efﬁcient antiviral host mechanism against NV infection. Moreover, NV
replication in Huh-7 cells seen after transfecting genomic NV RNA
(Guix et al., 2007) is inhibited if cells are pre-treated with the
supernatant from cells that have been transfected with Poly(I:C) to
induce IFN-α/β production (Guix and Estes, 2009). Finally, permissive
NV genome replication after transfecting NV RNA in Huh-7 cells does
not induce a strong type I IFN response (Guix and Estes, 2009).
However, Huh-7 cells lack some key components of the type I IFN
pathway (Li et al., 2005). Thus, it was worthwhile to test whether
PBMC-DCs might produce type I IFN responses following exposure to
the NV inoculum, since we found few of these cells expressing NV
proteins. The NV inoculum contained small amounts of residual
endotoxin due to its derivation from stool, so we analyzed whether
LPS present in this inoculummight preclude NV replication in cells by
inducing the type I IFN pathway using three different approaches. No
signiﬁcant induction of IFN-βmRNAwas identiﬁed 10 hpi, and the use
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or antibodies targeting IFN-α and IFN-β and their receptor did not
lead to increases in NV RNA production following inoculation of cells.
Thus, other cellular barriers are preventing NV replication in these
cells.
In conclusion, attempts to determine if NV grows in human CD11c+
DCs, monocyte-derived DCs andMΦ, cells of the hematopoietic lineage,
were unsuccessful, and cultivatable NVwas not recovered. These results
raise the question of whether NoV nucleic acid detected in the serum of
children with gastroenteritis (Takanashi et al., 2009) represents free
virus in serum or virus released from another subset of infected cells.
Future studies could examine this question in volunteers infected with
NV. Further studies are needed to elucidate NV tropism and to fully
understand NoV pathogenesis in humans. Such studies may facilitate
the development of a fully permissive cell culture system for human
NoV, which would then lead to the design of new therapeutic
treatments for these fastidious viruses.
Materials and methods
NV puriﬁcation from stools from a NV-infected volunteer
NV was puriﬁed from stool as previously described (Guix et al.,
2007). In brief, stools obtained 3 days post-NV inoculation from
volunteer #732 (Atmar et al., 2008) were prepared as ten percent
suspensions in 0.1 M phosphate-buffered saline (PBS)-0.5% Zwitter-
gent detergent (Calbiochem, Gibbstown, NJ), extracted with Vertrel
XF (Miller-Stephenson, Sylmar, CA) and clariﬁed by centrifugation for
10 min at 12,400×g. Virus in the supernatant was precipitated with
8% polyethylene glycol and 40 mM NaCl solution, and after centrifu-
gation, the pellet was suspended in 0.1 M PBS. The virus suspension
was centrifuged through a 30% sucrose cushion for 3 h at 124,000×g
and further puriﬁed by isopycnic cesium chloride (CsCl) gradient
centrifugation for 24 h at 150,000×g. Fractions were collected, and
densities were determined by measuring the refractive index of each
fraction. CsCl was removed from each fraction and suspended into
120 μl diethylpyrocarbonate-treated (DEPC) water. The titer of NV
genome copies in each fraction was determined by IMC/qRT-PCR
assay as described below. Endotoxin levels in CsCl puriﬁed NV and γ-
NV (see below), respectively, were determined by using the Pyrotell
Gel-Clot method (Associates of Cape Cod Incorporated), following the
manufacturer's protocol.
NV inactivation by gamma (γ)-irradiation
NVwas inactivated by γ-irradiation for use as a negative control to
monitor NV replication in cells. Initially, 5 μl of the NV puriﬁed from
stool was added into a 2 ml cryovial ‘o’ ring tube and was exposed to
γ-irradiation doses of 1, 2, 3, 6, or 12 kilo Grays (kGy) at RT using a
Gammacell-1000 Irradiator (Atomic Energy of Canada Ltd., Ontario)
with a Cesium-137 source, at a dose rate of 0.5 kGy/h. Unexposed NV
was left at RT for the same length of time as the exposed samples to
determine the effect of γ-inactivation on NV genomic RNA.
Immunomagnetic capture/real-time quantitative RT-PCR (IMC/qRT-PCR)
assay
NV RNA titers were measured in samples either from gradient
fractions after CsCl ultracentriﬁgation or from puriﬁed NV exposed to
different doses of γ-irradiation by IMC/qRT-PCR assay as previously
described with some modiﬁcations (Gilpatrick et al., 2000). In brief,
10 μl of a 1:1000 dilution of each gradient sample, or 10 μl of
undiluted, 1:10, 1:100, or 1:1000 dilutions from γ-irradiated samples,
were mixed with 1.2 ml of PBS containing 0.1% bovine serum albumin
(BSA, Sigma, Atlanta, GA) and 50 μl of polyclonal rabbit anti-rNV IgG
coupled to magnetic beads (1 μg/μl BioMag goat anti-rabbit IgG,Qiagen, Carol Stream, IL), in RNAse-free 2 ml tubes and incubated on a
rotating platform for 2 h at RT. Each sample was washed 3× with 0.1%
BSA/PBS. After the last wash, 35 μl of DEPC-treated water (Invitrogen,
Chicago, IL) was added to each sample and the suspended sample was
transferred into a RNAse-free 0.5 ml tube. RNA was released from the
NV particles by incubating each tube for 5 min at 95 °C. RNA was
analyzed by qRT-PCR with primers targeting the ORF1 region of NV as
previously described (Guix et al., 2007).
Fucosyltransferase 2 (FUT2) genotyping assay
DNAwas extracted from 200 μl of buffy coat of each donor using the
QIAamp DNA Blood Mini Kit (QIAGEN). A region of the FUT2 gene was
ampliﬁed using the following primers: forward 5′-CCCATCTTCAGAAT-
CACCCTGCCGGTGCTG-3′, and reverse 5′-TCGGCCGGCCCGTGGAAA-
CATCCCCAGGTA-3′, which anneal at nucleotide (nt) positions 280–
309 and 535–564, respectively, as previously described (Hutson et al.,
2005). Reactions were carried out in a ﬁnal volume of 50 μl using 2.5 U
AmpliTaq (Invitrogen) with a thermal program that consisted of an
initial denaturation step for 2 min at 95 °C, followedby35 cycles for 30 s
at 95 °C, 30 s at 65 °C, 1 min at 72 °C and a ﬁnal elongation for 10 min at
72 °C. Detection of the single nucleotide polymorphism of G428A (SNP)
was performed on 2 μl of the PCR product, the Custom TaqMan SNP
Genotyping Assay for the 428 SNP of the FUT2 gene designed by Dr. Le
Pendu, France (Applied Biosystems, Chicago, IL) and the TaqMan
GenotypingMasterMix (Applied Biosystems), in aﬁnal reaction volume
of 20 μl. The thermal program consisted of 40 cycles of ampliﬁcation
95 °C 10 min, 92 °C 15 s, and 60 °C 1 min, using the Applied Biosystems
7500 real-time PCR system, and applying the Allelic Discrimination
program (Applied Biosystems). Samples were tested in triplicate wells.
To assay for the A385T polymorphism, a fragment of the FUT2 genewas
ampliﬁed using the forward primer 5′-AACGACTGGATGGAGGAG-
GAATA-3′ and the reverse primer 5′-CTCATGCAGGCGAAGTGGC-3′
that span nt 355–412.
Reactionswere carried out as described above, and detection of the
SNP was performed as above using the Custom TaqMan SNP
Genotyping Assay for the 385 SNP of the FUT2 gene (Applied
Biosystems) with the following ﬂuorescent probes both at nt position
378–391: 5′-CCGCCACATCCCGG-3′ and 5′-CCGCCACTTCCCGG-3′.
Results were analyzed as described previously (Hutson et al., 2005).
Isolation and culturing of cell subsets from buffy coats of adult donors
DCs were derived from monocytes isolated from peripheral blood
mononuclear cells by the adherencemethod (PBMC-DCs). Buffy coats of
blood samples from healthy adult donors, blood group type O, were
purchased fromtheGulf Coast Regional BloodCenter (Houston, TX), and
PBMCs were isolated by density gradient centrifugation using Ficoll-
Paque PLUS following the manufacturer's procedure (GE Healthcare,
Pittsburgh, NJ). Following suspension of PBMCs into RPMI 1640 media
(Invitrogen) supplemented with 1% heat inactivated fetal bovine
serum (FBS) (Invitrogen) and incubated for 2 h at 37 °C and 5% CO2,
adherent cells (mostly CD14+ monocytes) were washed 3× with
media by removing ﬂoating cells. Adherent cells were suspended in
DC media [RPMI 1640 media supplemented with 10% heat inacti-
vated FBS (Invitrogen), 100 U/ml Penicillin, 100 μg/ml streptomy-
cin, 2 mM L-glutamine, 1 mM sodium pyruvate, 10 mMHepes, 1× β-
mercaptoethanol (Invitrogen), and 500 U/ml granulocyte macro-
phage-colony stimulator factor (GM-CSF) and 500 U/ml interleukin-
4 (IL-4) (R&D Systems, Minneapolis, MN) and incubated for at least
6 days at 37 °C in 5% CO2. DCs andMΦwere also derived from CD16+
and CD14+ monocyte subsets isolated from PBMCs. CD16+ mono-
cyteswere isolated by using the CD16+Monocyte Isolation Kit (Milteny
Biotec, San Francisco, CA), andCD14+monocyteswere isolated fromthe
ﬂow through fraction using CD14 microbeads following the manufac-
turer's protocol (Milteny Biotec). The CD16+ and CD14+ monocyte
9M.K. Lay et al. / Virology 406 (2010) 1–11subsets were incubated at 37 °C in 5% CO2, for at least 6 days, in DC
media to give rise to immatureCD16+DCs andCD14+DCs, respectively.
In some cases, monocyte subsets were incubated in MΦ media, which
consists of RPMI 1640 media supplemented with 10% heat inactivated
FBS, 100 U/ml Penicillin, 100 μg/ml streptomycin (Invitrogen) plus
10 ng/ml of human rM-CSF (R&D Systems), to give rise to CD16+ MΦ
and CD14+ MΦ, respectively. Medium and reagents were changed
every 3 days. CD11c+ blood DCs (CD11c+ DCs) were also isolated from
buffy coats by ﬂuorescent activated cell sorting (FACS) as previously
described (Reche et al., 2001). In brief, the DC-enriched population
(lineage negative cells) was obtained from PBMCs by negative selection
using a mixture of monoclonal antibodies (mAbs) against the lineage
markers CD3 (OKT3), CD14 (M5E2), CD16 (HB78), CD20 (L27), CD56
(B159), and CD235a (10F7MN) (BD Biosciences, San Jose, CA), followed
by the use of magnetic beads (Invitrogen and Miltenyi Biotec). The DC-
enriched population was subsequently stained with a mixture of
ﬂuorescein isothiocyanate (FITC)-labeledmAbs against lineagemarkers
including CD3 (SK7), CD14 (MØP9), CD16 (3G8), CD19 (HIB19) and
CD56 (NCAM16.2), APC-labeledanti-CD11c (Bly6) (BDBiosciences) and
paciﬁc blue-labeled anti-CD4 (OKT4; eBioscience, San Diego, CA). The
lineage negative, CD11c andCD4 double positive cellswere isolated by a
FACS-Aria™ cell sorter system (BD Biosciences) to reach N99% purity.
Viability of theCD11c+DCswasdeterminedby the standard trypanblue
dye-exclusion method. The CD11c+ DCs were cultured in RPMI
containing 10% FBS by seeding at a density of 1 to 3×105 cells/well in
200 μl volume in ﬂat-bottom 96-well plates.
Cell surface phenotyping analysis of PBMC- and isolatedmonocyte-derived
DCs
Phenotypic analysis of isolated monocytes and immature DCs was
performed by ﬂow cytometry. At day 0 (monocytes), 6 (PBMC-DCs) or
8 (CD16+ DCs and CD14+ DCs) of GM-CSF and IL-4 treatment, cells
were harvested and washed with cold 0.1 M PBS containing 2% FBS
(PBS/2% FBS). Subsequently, cells were stained in 100 μl of PBS/2%
FBS for 30 min at 4 °C with phycoerythrin (PE) or FITC-conjugated
mouse anti-human antibodies to: CD14, CD16, CD11c, CD1a, CD80,
CD83, CD3, CD40, CD31, CD56, and HLA-A,B,C (MHC class I); and HLA-
DR,DP,DQ (MHC class II) and in some cases, to CD209 (BD
Biosciences). FITC or PE-conjugated mouse anti-human IgG1 anti-
bodies were included as isotype controls. Cells were washed and
suspended in 200 μl of cold PBS/2% FBS and ﬁxed with 2%
paraformaldehyde. Stained cells were analyzed (5000 events per
sample) for single or double color immunoﬂuorescence with a BD
FACSCalibur system-dual-laser ﬂow cytometer (BD Biosciences). Data
were acquired and analyzed using CellQuest software (Becton
Dickinson). For analysis of CD103 and CX3CR1 expression in PBMC-
DCs, a similar staining procedure was performed including: FITC-
labeled anti-human CD11c (Clone 3.9, mouse IgG1, eBiosciences), PE-
labeled anti-human CD103 (Clone B-Ly7, mouse IgG1, eBiosciences),
tri-color (TC)-labeled anti-human CD3 (Clone S4.1, mouse IgG2a,
Caltag Laboratories), APC-Cy7 labeled anti-human CD11b (Clone
ICRF44, mouse IgG1, BD Biosciences) and Alexa Fluor 647 labeled anti-
human CX3CR1 (Clone2A9-1 Rat IgG2b, Biolegend). The stained cells
were acquired on a Cyan ADP (Dako, Carpinteria, CA), and data were
analyzed by using FlowJo software (Tree Star, Ashland, OR).
NV inoculation of PBMC monocyte-derived DCs/MΦ and CD11c+ DCs
After at least 6 days of culture, PBMC-DCs, CD16+ DCs and CD14+
DCs were seeded at 3 to 7×105 cells/well. CD16+ MΦ, CD14+ MΦ,
and sorted CD11c+ DCs were seeded at 2×105 cells/well. Seeded cells
were exposed to media only (mock), to NV (viral doses were in the
range of 275 to 1941 NV genome copies/cell) or to γ-irradiated NV (4
or 4.5 kGy). Treated cells were incubated for 2 h at 37 °C. Super-
natants were removed and CD11c+ DCs were suspended into RPMIcontaining 10% FBS. After 3 washes with RPMI media, PBMC-DCs,
CD16+ DCs or CD14+ DCs were suspended into DC media. CD16+MΦ
or CD14+ MΦwere suspended into MΦmedia. In some experiments,
PBMC-DCs were also treated with 10 μg/ml polymyxin B (PB, Sigma-
Aldrich, St. Louis, MO); 1 μg/ml LPS (Sigma-Aldrich); 50 μg/ml poly-
nosinic polycytidylic acid sodium (Poly [I:C], Sigma-Aldrich); or a
cocktail of rabbit polyclonal anti-IFN-α Abs (2000 neutralizing U/ml),
rabbit polyclonal anti-IFN-β Abs (1000 neutralizing U/ml), and mouse
anti-IFN-α/β receptor mAb (10 μg/ml, MMHAR-2; PBL Biomedical
Laboratories). These treatments were added at the time of inoculation
and kept in the media after the inoculum was removed. Treated cells
were incubated at 37 °C in 5% CO2 and harvested for viral RNA
ampliﬁcation analysis by qRT-PCR at 0, 24, 48, 72 or 144 h post-
inoculation (hpi) and protein expression analysis by IF at 24 and 72 hpi.
Inoculation of cells from each donor was performed in triplicate.
Detection of NV proteins and cell markers in inoculated PBMC-DCs by IF
assays
Immunoﬂuorescence (IF) analysis was performed as previously
reported (Guix et al., 2007), except for the following modiﬁcations:
for dual-staining for NV structural and nonstructural proteins at 24 or
72 hpi, cells were incubated with primary antibodies and added to the
wells at the appropriate dilution in 0.1 M PBS–5% BSA (1:1000
dilution for guinea pig polyclonal anti-VP1 with 1:1000 rabbit
polyclonal anti-VPg; or guinea pig polyclonal anti-VP1 with 1:2000
for mouse polyclonal anti-polymerase serum. The same dilutions of
their respective pre-immune sera were used as controls). For dual-
staining of VP1 and CD103, anti-VP1 antibody and 1:200 dilution of a
rabbit polyclonal anti-CD103 antibody (Integrin aE [H-260], Santa
Cruz Biotechnology, Santa Cruz, CA) in 0.1 M PBS–5% BSA was added.
Samples were incubated overnight at 4 °C. Cells were washed 3× with
0.1 M PBS and incubated for 2 h at RT in a 1:1000 dilution of the
corresponding secondary antibodies conjugated with Alexa 488, or
Alexa 594 (Invitrogen). Cells were rinsed 3× with 0.1 M PBS. Nuclei
were stained with 300 nM 4′,6′-diamidino-2-phenylindole (DAPI,
Invitrogen) for 5 min at RT. For dual-staining of VP1 and CX3CR1, cells
were blocked at RT for 2 h in 0.1 M PBS–5% BSA. Rabbit polyclonal
anti-CX3CR1 antibody (Abcam) was added to the wells at 1:400
dilution in 0.1 M PBS–5% BSA and incubated overnight at 4 °C. After
washes, cells were incubated for 2 h at RT with the respective
secondary antibody conjugated with Alexa 488 in 0.1 M PBS–5% BSA.
After washing, cells were permeabilizedwith 0.5% Triton X-100–0.1 M
PBS for 20 min at RT. Cells were stainedwith primary antibody for VP1
staining as shown above. IF and cell morphology analyses were
performed using an Olympus IX-70 inverted microscope and Micro-
ﬁre digital camera.
RNA isolation of inoculated DCs and MΦ
RNA was extracted from total cell and supernatant samples using
TRIzol LS (Invitrogen) according to the manufacturer's protocol at the
indicated times post-inoculation. Samples were stored in RNAse-free
2 ml tubes at −80 °C.
Real time quantitative (q)RT-PCR assay
Extracted NV RNA was quantiﬁed by qRT-PCR as previously
described (Guix et al., 2007). Brieﬂy, a standard curve for absolute
RNA quantiﬁcation was generated in every assay by using RNA
transcripts produced by in vitro transcription of a cDNA that contained
ORF1- and ORF2-targeted regions (nt 4487 to 5671). Primers and
probes used to amplify the ORF1 (nt 4641 to 4715) genomic region of
NV have been previously described (Asanaka et al., 2005). Standard
curves included ﬁve ten-fold dilutions and three replicate wells for
each dilution. All samples were analyzed in at least triplicate wells.
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mix reagent kit (Applied Biosystems) in an Applied Biosystems 7500
real-time PCR system. The thermal program consisted of 30 min at
48 °C, followed by 10 min at 95 °C, 45 cycles of 15 s at 95 °C and 1 min
at 60 °C. For IFN-β mRNA expression analysis in PBMC-DCs treated
with mock, γ-NV, NV, NV+PB, LPS or Poly (I:C) after 10 h, a
comparative (CT) method or relative quantiﬁcation (RQ) qRT-PCR
analysis was performed using the IFN-β Taqman(R) Gene Expression
Assay (Applied Biosystems). Normalization versus beta (β)-actin RNA
was performed on these samples using the TaqMan β-actin control
reagents (human) (Applied Biosystems).
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